Nasdaq Copenhagen · Nasdaq First North Growth Market (Copenhagen) · below €300M
Danish Microcap Stocks Screener
Screen Danish microcap stocks below DKK 2.2B (~€300M) on Nasdaq Copenhagen — including First North Copenhagen's life sciences and technology companies.
What makes Denmark microcaps worth screening
- First North Copenhagen has an unusually high density of pharmaceutical, biotech, and medical device microcaps — spinoffs from the Danish life sciences cluster centred around Copenhagen and Aarhus universities
- Danish biotech microcaps have structural connections to Novo Nordisk and Leo Pharma research ecosystems — pipeline assets and licensing potential that generalist screeners cannot identify from fundamentals alone
- Nasdaq Copenhagen reporting standards are high for an alternative market — governance, board independence, and financial disclosure requirements are comparable to main market standards and significantly above peer alternative markets
- Danish stocks trade in DKK which is pegged to EUR in a narrow band — minimising currency risk for eurozone-based investors while still accessing a distinct national equity market
Where Denmark microcaps are listed
Nasdaq First North Growth Market (Copenhagen)
Part of Nasdaq Copenhagen. Most Denmark companies below €300M market cap are listed on this alternative or growth segment — lighter listing requirements, same exchange oversight, and DKK-denominated trading.
Exchange code in ScreenerHero: CPH
How to screen Denmark microcap stocks
1. Set exchange + market cap
Select CPH in the exchange filter. Set market cap maximum to €300M (or the DKK equivalent — equivalent in your target range). Sort by market cap ascending to start from the smallest names.
2. Apply quality filters
Add ROE > 8% and positive profit margin to filter the profitable subset of the microcap universe. Debt/equity below 1.5 removes overleveraged names. This combination narrows the universe to companies worth deeper analysis.
3. Find the cheapest
Sort by P/E or EV/EBITDA ascending within your quality-filtered list. Click any result to open the full instrument page — price history, fundamentals breakdown, and upcoming events.
Screen Denmark microcap stocks now
Filter by P/E, ROE, EV/EBITDA, margins, beta, and dividend yield across all Nasdaq Copenhagen listings below €300M. Free, no account needed.
Common questions
What is First North Copenhagen and how does it relate to Danish microcaps?
Nasdaq First North Growth Market (Copenhagen) is the alternative market for Danish companies below the main Nasdaq Copenhagen size threshold. It lists 70+ companies, primarily in healthcare, technology, and consumer sectors. Reporting and governance requirements are high by alternative market standards.
Why is the Danish biotech microcap sector particularly interesting?
Denmark has world-class pharmaceutical and biotech research institutions. First North Copenhagen lists multiple early-stage and revenue-stage biotech companies that emerged from Danish university and hospital research programs. The connection to Novo Nordisk's extensive supplier and partner network means many small Danish healthcare companies have institutional validation of their technology.
How do I screen Danish microcap stocks in ScreenerHero?
Select CPH in the exchange filter and set market cap maximum to approximately DKK 2,200M (€300M equivalent). Note that many Danish biotech microcaps will not have P/E data (pre-revenue). Use market cap max with sector = Healthcare to see the biotech universe, or add profit margin > 0% to focus on revenue-generating companies. For industrial microcaps, ROE > 8% works well as a quality filter.
Can I screen Denmark microcaps alongside other European markets?
Yes — the ScreenerHero screener lets you select multiple exchanges simultaneously. Combine CPH with other European exchanges and apply the same market cap maximum to run cross-country microcap screens with identical fundamental filters.
Related screeners
Other country microcap screeners:
Denmark microcaps. Screened in seconds.
The Nasdaq Copenhagen companies below €300M that major screeners miss. Dense tables, fast filters, all active listings — including the ones with no analyst coverage. Free, no account needed. Premium at €25/mo adds alerts and exports.